Professor Sir Alimuddin Zumla

Ms Alimuddin ZumlaTel: 07901 638 375
Fax: 020 7679 9311


Professional background

Professor Sir Alimuddin Zumla is Professor of Infectious Diseases and International Health at University College London. He is also consultant infectious diseases physician at UCLH, honorary consultant at Public Health England and at Royal Free Hospital, and holds a UK NIHR Senior Investigator Award. His London and overseas research activities span the interface between clinical investigation and biomedical science, with the long-term goals of understanding the pathogenesis of important killer infectious diseases afflicting adults and children, and developing methods for rapid diagnosis, better treatment and control.

Sir Ali's research embraces the principles of evidence-based medicine, contributing knowledge through specific clinical, research and training activities in the UK, Europe and in sub-Saharan African countries. A very successful programme of research and training between UCL, UK institutions, and several African, European and USA institutions has been developed. He is visiting Professor to several European and African universities serves on many national and international advisory committees. His global leadership of infectious diseases has earned him numerous prestigious prizes, medals and awards and his work reflects the UK NHS's influence on and contributions to global health.


Research interests

  • Respiratory tract infections
  • Tuberculosis
  • Emerging and re-emerging infections
  • Tropical diseases
  • Antimicrobial resistance
  • Rapid diagnostics for respiratory infections
  • Endocarditis
  • Urinary tract infections
  • TB drug and new diagnostics clinical trials
  • Biomarkers
  • Host-directed therapies


476 Pubmed Articles (105 in The Lancet journals, 8 in NEJM, 6 Nature journals) and has published 19 medical textbooks

Journal articles: Selected list out of 476 articles on Pubmed

  1. Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, Marais B, Schito M,
    Churchyard G, Swaminathan S, Hoelscher M, Zumla A.
    Tuberculosis – Advances in Development of New Drugs, Treatment Regimens, Host-Directed Therapies and Biomarkers. The Lancet Infectious Diseases. 2016:16:4. e34-e46. doi: 10.1016/S1473-3099(16)00070-0.
  2. Sotgiu G, Tiberi S, D’Ambrosio L, Centis R, Zumla A, Migliori G. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis.
    The Lancet. 2016: Jun 18;387(10037):2486-7.
  3. Dar O, Hasan R, Schlundt J, Harbarth S, Caleo G, Dar FK, Littmann J, Rweyemamu, Buckley EJ, Shahid M, Kock R, Li HL, Giha H, Khan M, So AD, Bindayna KM, Kessel A, Pedersen HB, Permanand P, Zumla A, Rottingen JA, Heymann D. Exploring the evidence base for national and regional policy interventions to combat antimicrobial resistance. The Lancet 2016. Jan 16;387(10015):285-95.
  4. Khan M, Osei-Kofi A, Omar A, Kirkbride H, Kessel A, Abbara A, Heymann D, Zumla A, Dar O. Pathogens, prejudice and politics: defining the role of the global health community in the European refugee crisis.
    The Lancet Infectious Diseases. 2016: Aug;16(8):e173-7. doi: 10.1016/S1473-3099(16)30134-7
  5. Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, Vilaplana C, Yeboah-Manu D,
    Chakaya J, Ippolito G, Azhar E, Hoelscher M, Maeurer M; Host-Directed Therapies Network consortium. Host-Directed Therapies for Infectious Diseases – Current Status, Recent Progress and Future Prospects. The Lancet Infectious Diseases. 2016. Apr;16(4):e47-63. doi: 10.1016/S1473-3099(16)00078-5
  6. Ippolito G, Lanini S, Brouqui P, Di Caro A, Vairo F, Fusco FM, Krishna S, Capobianchi MR, Kyobe-Bosa H, Puro V, Wölfel R, Avsic-Zupanc T, Ioannidis JP, Portella G, Kremsner P, Dar O, Bates M, Zumla A. Non-randomised Ebola trials –lessons for optimal outbreak research. The Lancet Infectious Diseases. 2016. 16:4: 407-408.
  7. Bates M, Mudenda V, Shibemba A, Kaluwaji J, Tembo J, Kabwe M, Chimoga C, Chilukutu L,
    Chilufya M, Kapata N, Hoelscher M, Maeurer M, Mwaba P, Zumla A.
    Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study. The Lancet Infectious diseases. 2015;15(5):544-51
  8. Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, Kapata N, Nyirenda T, Chanda D,
    Mfinanga S, Hoelscher M, Maeurer M, Migliori GB. Tuberculosis treatment and
    management--an update on treatment regimens, trials, new drugs, and adjunct therapies.
    The Lancet Respiratory Medicine. 2015;3(3):220-34.
  9. Lanini S, Zumla A, Ioannidis JP, Di Caro A, Krishna S, Gostin L, Girardi E, Pletschette M, Strada G, Baritussio A, Portella G, Apolone G, Cavuto S, Satolli R, Kremsner P, Vairo F, Ippolito G. Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in West Africa? The Lancet Infectious diseases. 2015;15(6):738-45.
  10. Zumla A, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS, Maeurer M. Towards host-directed therapies for tuberculosis. Nature Reviews Drug Discovery. 2015; 14(8):511-2.
  11. Drosten C, Meyer B, Muller MA, Corman VM, Al-Masri M, Hossain R, Madani H, Sieberg A, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Hajomar W, Albarrak AM, Al-Tawfiq JA, Zumla AI, Memish ZA. Transmission of MERS-coronavirus in household contacts. New England Journal of Medicine. 2014;371(9):828-35.
  12. Mfinanga SG, Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, Yimer G, Ezechi O, Connolly C, Kapotwe V, Muwonge C, Massaga J, Sinkala E, Kohi W, Lyantumba L, Nyakoojo G, Luwaga H, Doulla B, Mzyece J, Kapata N, Vahedi M, Mwaba P, Egwaga S, Adatu F, Pym A, Joloba M, Rustomjee R, Zumla A, Onyebujoh P. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infectious Diseases. 2014.14(7):563-71
  13. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla A, Memish ZA. Hospital outbreak of Middle East respiratory syndrome coronavirus. New England Journal of Medicine. 2013;369(5):407-16.
    TEXTBOOKS PUBLISHED (Selcted 2 out of 20)
    36 chapters, 120 authors. Publisher: Cold Spring Harbour, USA
    Reviewed in LID:
  15. Cook GC and Zumla A. (Editors):
    Publishers: Saunders Elsevier Publishing Group, London, (89 chapters and 122 authors). ISBN 978-1-4160-4470-3.Hardback version. ISBN 978-1-4160-4471-0Online access available. Excellent book reviews. Review in the Lancet by a reviewer from the World Organization called it a ‘magnificent global classic’.

GMC/GDC number: 3050424